vebicorvir
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2020 (NCT04637139)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
- Core antigenINHIBITOR
Core antigen inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NCc1cnc(C(F)(F)F)s1)c1ccc2c(c1)NC(=O)c1ccccc1S2(=O)=O- Mol. weight
- 467.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650324 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05238844 | Phase 2 | Apr 11, 2022 | Antios Therapeutics, Inc |
| NCT04637139 | Phase 1 | Nov 2, 2020 | Assembly Biosciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antios Therapeutics, Inc | For profit | 1 | 1 | 1 | 2022 |
| Assembly Biosciences | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1